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Abstract
Background: Progressive multifocal leukoencephalopathy (PML) is an opportunistic central nervous system- (CNS-) infection
that typically occurs in a subset of immunocompromised individuals. An increasing incidence of PML has recently been
reported in patients receiving monoclonal antibody (mAb) therapy for the treatment of autoimmune diseases, particularly
those treated with natalizumab, efalizumab and rituximab. Intracellular CD4+-ATP-concentration (iATP) functionally reflects
cellular immunocompetence and inversely correlates with risk of infections during immunosuppressive therapy. We
investigated whether iATP may assist in individualized risk stratification for opportunistic infections during mAb-treatment.
Methodology/Principal Findings: iATP in PHA-stimulated, immunoselected CD4+-cells was analyzed using an FDA-
approved assay. iATP of mAb-associated PML (natalizumab (n = 8), rituximab (n = 2), efalizumab (n = 1)), or other cases of
opportunistic CNS-infections (HIV-associated PML (n = 2), spontaneous PML, PML in a psoriasis patient under fumaric acids,
natalizumab-associated herpes simplex encephalitis (n = 1 each)) was reduced by 59% (194.5629 ng/ml, mean6SEM) in
comparison to healthy controls (HC, 479.9619.8 ng/ml, p,0.0001). iATP in 14 of these 16 patients was at or below 3rd
percentile of healthy controls, similar to HIV-patients (n = 18). In contrast, CD4+-cell numbers were reduced in only 7 of 15
patients, for whom cell counts were available. iATP correlated with mitochondrial transmembrane potential (DYm) (iATP/
DYm2correlation:tau = 0.49, p = 0.03). Whereas mean iATP of cross-sectionally analysed natalizumab-treated patients was
unaltered (448.7612 ng/ml, n = 150), iATP was moderately decreased (316.2626.1 ng/ml, p = 0.04) in patients (n = 7) who
had been treated already during the pivotal phase III trials and had received natalizumab for more than 6 years. 2/92 (2%)
patients with less than 24 months natalizumab treatment revealed very low iATP at or below the 3rd percentile of HC,
whereas 10/58 (17%) of the patients treated for more than 24 months had such low iATP-concentrations.
Conclusion: Our results suggest that bioenergetic parameters such as iATP may assist in risk stratification under mAb-
immunotherapy of autoimmune disorders.
Citation: Haghikia A, Perrech M, Pula B, Ruhrmann S, Potthoff A, et al. (2011) Functional Energetics of CD4+-Cellular Immunity in Monoclonal Antibody-Associated
Progressive Multifocal Leukoencephalopathy in Autoimmune Disorders. PLoS ONE 6(4): e18506. doi:10.1371/journal.pone.0018506
Editor: Mehrdad Matloubian, University of California San Francisco, United States of America
Received October 20, 2010; Accepted March 9, 2011; Published April 20, 2011
Copyright:  2011 Haghikia et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the German Bundesministerium fu¨r Bildung und Forschung (BMBF), German competence Network Multiple Sclerosis
(KKNMS), No. 01GI0914. This work was supported by a limited grant from Biogen Idec for purchasing the bioenergetic kit material. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: S.G. is an employee of Biogen Idec and contributed to study design. S.G. and Biogen Idec supported the study by a limited grant from
Biogen Idec for purchasing the bioenergetic kit material. The authors declare that this circumstance does not alter their adherence to all the PLoS ONE policies on
sharing data and materials. A.H., H.W., T.Z., R.G. and A.C. have received speakers’ honoraria and limited research support from Biogen Idec, Bayer Health, Merck
Serono and Teva. All other authors declare no competing financial interests.
* E-mail: andrew.chan@rub.de
Introduction
PML is a demyelinating, potentially fatal opportunistic infection
of the CNS incited by the JC polyomavirus (JCV). Despite a high
seroprevalence of anti-JCV-antibodies in healthy adults, estimated
to be ,80%, development of PML in non-immunocompromised
individuals is very rare [1]. Conditions that predispose to PML are
typically linked to defects of CD4+-/CD8+-cell-mediated immu-
nity, with HIV infection accounting for about 80% of all new
PML-cases [2,3]. Recently, however, cases of PML have been
observed upon immunotherapy with monoclonal antibodies
(mAbs), including natalizumab, rituximab and efalizumab, that
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have been approved for the treatment of multiple sclerosis (MS),
Crohn’s disease; non-Hodgkin lymphoma, chronic lymphocytic
leukaemia, rheumatoid arthritis; and psoriasis, respectively [4–7].
Of these mAb immunotherapy-associated PML cases, 85 have been
confirmed as of January 7th 2011 to be specifically natalizumab-
associated. All cases had received natalizumab in the drug’s post-
marketing phase during which it was marketed along with a ‘‘Black
Box’’ warning that included the risk of PML development (www.
fda.org).
While the precise pathogenic mechanism of mAb-associated
PML remains elusive, the involvement of CD4+- and CD8+-
lymphopenia is postulated as a risk factor in at least some of these
patients [5]. Moreover, rapid reconstitution of CNS-immunosur-
veillance is predicted to lead to the control of PML [8]. However,
the effective resurrection of the immune system after removal of
respective mAb with plasma exchange (PLEX) and/or immuno-
adsorption (IA) is associated with an immune reconstitution
inflammatory syndrome (IRIS), that is characterised by an
inflammatory brain infiltrate consisting of lymphocytes and
multinucleated cells [9,10].
Additional evidence suggests an important role for CD4+-/
CD8+-cell-mediated immunity in the anti-JCV immune response.
Recognition of extracellular, MHC-class II-presented viral anti-
gens by CD4+-cells and subsequent activation of cytotoxic CD8+-
cells appears to be important for the control of JCV-infected cells
[11–14], and an association of HLA-class I haplotypes and CD8+-
cellular responses with prognosis of PML has been reported
[15,16].
For a resting T-cell to become an activated immune effector cell
it must experience a phenotypic and functional shift that requires
an enhanced supply of ATP-generating metabolites to meet the
increased bioenergetic demands of the activated cell state [17].
The ability of lymphocytes to import energy-carrying metabolites
and to upregulate oxidative phosphorylation appears to be critical
in the maintenance of effective immune responses [17].
Here we set out to assess bioenergetic properties as a measure of
cellular immunocompetence in PML and other opportunistic
CNS-diseases. We used an FDA-approved assay for the detection
of cell-mediated immunity in an immunosuppressed population
(FDA no. k013169). This assay measures ATP-concentration in
CD4+-cells (iATP), which correlates with cytokine secretion and T-
cell proliferation and thus serves as a measure of T-cell activation
[18,19]. Furthermore, in immunosuppressed renal transplant
recipients, low iATP has been found to be associated with the
risk of reactivation of BK-virus, another opportunistic human
polyomavirus similar to JCV [20]. Our data, obtained using
samples from MS patients under mAb therapy and in pathogen-
etically diverse PML patients as well as HIV patients were also
corroborated through a biochemically independent method.
Results
Reduced CD4+-iATP in PML-patients, in patients with
opportunistic CNS-infections and HIV-patients
As depicted in figure 1, both German natalizumab-associated
PML cases for whom blood samples were available at the time
Figure 1. Intracellular CD4+-ATP-concentrations in natalizumab-associated PML. MS patients who developed progressive multifocal
leukoencephalopathy (PML) under natalizumab-treatment. For two patients (PML nataliz 1 and 2) samples were available at time point of diagnosis
(before plasma exchange/immunoadsorption; PLEX/IA), immediately after and at different time points after PLEX/IA as indicated. For PML nataliz 3–8
samples were only available during/after therapy; results are shown immediately after PLEX/IA (PML after PLEX) and at least one week after PLEX/IA
(PML 7 days to 5 months after PLEX). Total number of CD4+-cells per microliter (ml) and clinical/therapeutic course are shown above respective data
points; arrows indicate time point of plasma exchange (PLEX/IA) for mAb-elimination. Black bar indicates mean iATP-values, red bar 3rd percentile of
healthy controls.
doi:10.1371/journal.pone.0018506.g001
iATP in mAb-Related Infections
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point of diagnosis exhibited very low intracellular ATP in
CD4+-cells (iATP) in the range of the 3rd percentile of healthy
controls (235.3 ng/ml; PML 1 nataliz 243.5 ng/ml, PML 2
nataliz 238.9 ng/ml). Immediately after plasma exchange/
immune adsorption (PLEX/IA) to eliminate remaining mAb,
iATP increased strongly to normal values (fig. 1). This was
clinically followed by development of IRIS 4 weeks later [9]. In
the remaining 6 patients with natalizumab-associated PML, first
samples were only available during/after PLEX (PML nataliz
3–8, fig. 1). In 4 of these patients, iATP was elevated during
PLEX but decreased strongly after PLEX to low ranges (PML
nataliz 3) or even below 3rd percentile of HC (PML nataliz 4
and 5, fig. 1).
HIV patients at risk for opportunistic infections exhibited
significantly lower iATP (227.2627.7 ng/ml, p,0.0001) in
comparison to HC (479.9619.8 ng/ml). Likewise, strongly
decreased iATP below/at 3rd percentile of HC was also evident
for a spontaneous case of PML (PML spontaneous 111.5 and
106.2 ng/ml, fig. 2), and the HIV-associated PML cases (PML
HIV-1 168.9 ng/ml, PML HIV-2 6.6 ng/ml, fig. 2). Further-
more, a psoriasis patient with PML while undergoing treatment
with fumaric acid (PML psoriasis 108 ng/ml, fig. 2) and a
patient with natalizumab-associated herpes simplex virus-
encephalitis (HSV-encephalitis nataliz 260.2 ng/ml, fig. 2)
revealed dramatically decreased iATP-levels. Strongly reduced
iATP was also apparent in a patient with rituximab-associated
PML (PML rituximab-1 56.9 ng/ml, fig. 2) and two patients
with lethal PML-outcome after rituximab- (PML rituximab-2
195.2 ng/ml, fig. 2) and efalizumab- (PML efalizumab
210.4 ng/ml) therapy respectively, tested several weeks after
PLEX (fig. 2). In samples from all 16 patients with opportunistic
CNS-infections before or at least one week after PLEX, iATP
was reduced by 59% in comparison to HC (194.5629 ng/ml,
p,0.0001). Fourteen of these 16 patients had very low levels at/
below 3rd percentile of HC.
Each CD4+-iATP sample was also analyzed without PHA-
stimulation with no major differences observed (data not shown).
We addressed further the question of whether iATP as a functional
measure of immune cellular responsiveness is independent of total
CD4+ cell counts in the different cohorts analysed. For this
purpose we correlated iATP vs. total CD4+ cell counts in n = 286
samples - apart from patients with opportunistic infections -
consisting of healthy controls, MS patients devoid of immuno-
modulatory therapies and MS patients with natalizumab treat-
ment. Value of iATP as a measure of responsiveness rather than
depending on total cell numbers was reflected by the low
correlation coefficient (R2 = 0.07). iATP in CD8+-cells analyzed
in 10 patients with opportunistic CNS-infections did not
demonstrate clear differences, nor did CD8+-cell numbers
(CD8+-cells in HC 462.1633.6/ml, in opportunistic CNS-
infections 578.5690/ml).
CD4+-iATP reveals higher sensitivity than CD4+-cell
counts in PML-patients, in patients with opportunistic
CNS-infections and HIV-patients
Figure 3 correlates CD4+-iATP with CD4+-cell counts in
patients with PML (mAb-associated and other etiologies) and the
HIV-cohort. iATP was independent from CD4+-cell count
(Pearson r = 0.19, R2 = 0.04, p = 0.3). Whereas a strong reduction
of iATP was observed in all but two patients, only 7 of 15 patients
Figure 2. Intracellular CD4+-ATP-concentrations in mAb-asso-
ciated opportunistic CNS-infections. Patients with progressive
multifocal leukoencephalopathy (PML) without or with preceeding
mAb-therapy. iATP levels of HIV patients were significantly lower than
the HC cohort (p,0.0001). For patients with PML occurring under
efalizumab or rituximab therapy and HSV-encephalitis under natalizu-
mab, samples were only available after PLEX, as indicated. All other
patients had not received PLEX. Total number of CD4+-cells per
microliter (ml) and clinical course are shown above respective data
points. HIV: HIV-patients at risk for opportunistic infections (see table 1
for details). Black bar indicates mean iATP values and red bar 3rd
percentile of healthy controls.
doi:10.1371/journal.pone.0018506.g002
Figure 3. Relationship between total number of CD4+-cells and
intracellular CD4+-ATP-concentrations. The X-axis depicts CD4+ -
cell number per ml, y-axis intracellular CD4+-concentrations (iATP; ng/
ml) of patients with PML and HIV-patients (black dots) at risk for
opportunistic infections. Red dots indicate natalizumab-associated PML,
green dots other PML cases (HIV-/rituximab-/efalizumab-associated or
without previous immunotherapy). Red lines: 3rd percentile of healthy
controls.
doi:10.1371/journal.pone.0018506.g003
iATP in mAb-Related Infections
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with opportunistic CNS-infections, for whom cell counts were
available exhibited reduced CD4+-cell numbers.
Effects of plasma exchange (PLEX) on CD4+-iATP
To further investigate if the increase of iATP observed in
natalizumab-associated PML-patients after plasma exchange was a
direct effect of PLEX, we also analyzed patients undergoing PLEX
for treatment of other neuroimmunological diseases. Five, of
whom 4 were MS patients and one patient suffering from a specific
from of peripheral neuropathy with monoclonal gammopathy,
were analyzed for CD4+-iATP at the time-points described in the
section containing patients’ characterics.
According to the therapy consensus groups’ recommendation in
Germany, Switzerland and Austria (MSTKG), for MS patients not
responding to primary relapse therapy with high dose intravenous
corticosteroids, PLEX is an appropriate therapeutic escalation
option. Monoclonal gammopathy of undetermined significance
(MGUS) is a paraproteinemic disorder and a possible cause for
slowly progressive symmetric distal sensorimotor neuropathy.
PLEX is indicated as a therapeutic option for this neurologic
disorder.
Also in these patients iATP was increased by 62%
(714.46122 ng/ml) when compared to concentrations prior
to PLEX (441.56103 ng/ml, p,0.04). This indicated that
PLEX-associated increase of iATP in PML patients was at least
partly independent from the removal of natalizumab and
dynamics of JC virus infection and supports previous reports
on direct effects of PLEX on parameters of cellular immunity
[21–23].
CD4+-iATP correlates with mitochondrial transmembrane
potential (DYm) as functional measure of cellular
energetics
To corroborate iATP-data with a biochemically independent
assay, mitochondrial transmembrane potential (DYm) was inves-
tigated in CD4+-cells by flow-cytometry. A clear correlation of
DYm with iATP-levels could be demonstrated in the analysed
samples (iATP/DYm2correlation:tau = 0.49, p = 0.03, n = 12).
Tetramethyl rhodamine methylester (TMRM), which was used
for this purpose, is particularly suitable to assess DYm as its
hydrophilic structure allows crossing plasma membranes. At the
same time, its cationic character leads to accumulation in
negatively charged compartments as it is the case for the inner
mitochondrial membrane.
Natalizumab may affect CD4+-iATP in a time dependent
manner
As depicted in figure 4, in cross sectional natalizumab-treated
patients (mean therapy duration 23 months, range 1–78) mean
iATP revealed no significant difference (448.7612 ng/ml) in
comparison to healthy controls (HC, 479.9619.8 ng/ml) or
untreated MS-patients (465.9619.8 ng/ml). Also in vitro experi-
ments with natalizumab short term incubation vs. isotype control
did not show any alteration in CD4+-iATP levels (data not shown).
However, when separated according to therapy duration, a trend
towards a decrease in mean iATP was observed in patients treated
for more than 24 months (436620.2 ng/ml at 25–36 months,
patients treated for less than 24 months: 466.7615.4 ng/ml,
Figure 4. Intracellular CD4+-ATP-concentrations (iATP) of natalizumab-treated Multiple Sclerosis patients. Cross-sectional iATP in
multiple sclerosis (MS) patients without immunotherapy (n = 70) or under natalizumab-treatment (n = 157). Right side of graph: analysis of
natalizumab-treated MS-patients according to treatment duration given in months (mo). When compared to MS patients devoid of any
immunomodulatory treatment, MS patients undergoing natalizumab therapy for more than 68 months revealed a moderately significant decrease of
CD4+-iATP levels (*p = 0.04). Black bars: mean iATP values, red bar indicates 3rd percentile of healthy controls.
doi:10.1371/journal.pone.0018506.g004
iATP in mAb-Related Infections
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p = 0.2, fig. 4). 7 patients who had received natalizumab for more
than 6 years already during the pivotal phase III-SENTINEL trial
exhibited reduced mean iATP (316.2626 ng/ml at 68–78
months, p = 0.04, fig. 4, right side). In addition, whereas 2/92
(2%) patients who were treated for less than 24 months revealed
very low iATP at or below the 3rd percentile of HC, 10/58 (17%)
of the patients treated for more than 24 months had such low
iATP-concentrations. Preliminary data on a small number of
patients (n = 6) who discontinued natalizumab after 23.5 months of
therapy (mean 6 2.8 months) indicates an increase of iATP after
treatment cessation (iATP before treatment discontinuation
413664.3 ng/ml, iATP after cessation 570.8679.9 ng/ml). This
observation supports our findings on decreased iATP dependent
on natalizumab treatment duration, with potential reversal after
treatment cessation.
Discussion
Despite an increasing number of mAb-associated PML cases, so
far no surrogate parameters have been identified that can
effectively assist in individual disease risk assessment. Our main
finding is strongly reduced iATP as a bioenergetic parameter of
CD4+ T-cell function in mAb-associated PML-patients and
patients with pathogenetically diverse opportunistic CNS-infec-
tions. CD4+ T-cell function, as determined by iATP proved to be
more sensitive than mere CD4+-cell counts, a finding that was
further supported by assessment of mitochondrial transmembrane
potential as a biochemically independent method. Finally, our
data indicates a decrease of iATP in MS-patients treated with
natalizumab for more than 24 months, an interval during which
an increased risk of PML development has been observed.
MAb-associated PML is likely the result of a complex
combination of several pathogenic steps. Some commonly cited
hypotheses involve alterations in peripheral cell-mediated immu-
nity, mobilization of JCV-carrying CD34+-hematopoetic stem
cells/pre-B-cells, neurotropic JCV-transformation, and mecha-
nisms at the blood-brain barrier/CNS-parenchyma [35–39]. Here
we have focussed on peripheral cellular immune functions as
disorders that predispose to PML (e.g. HIV and leukemia) mainly
involve defects of the peripheral immune system. In addition,
several lines of evidence point to the important role of an efficient
CD4+- and CD8+-cellular immune response in the control of JC-
virus induced PML [11–14]. In HIV-associated PML, an antigen-
specific CD8+-cell response in which the antigen was presented by
an MHC class I molecule encoded by he HLA-A*0201 allele has
been shown to correlate with prognosis and disease outcome
[15,16]. Various studies have concluded that specific anti-JC virus
antibody responses are not sufficient to prevent or restrict PML
[23], which further support the key role of cellular immunity that
is needed in response to JCV infection.
Intracellular ATP serves as a measure of CD4+ T-cell
functionality that correlates well with other markers of T-cell
activation such as cytokine secretion and proliferation [18,19].
The iATP level detected after mitogen stimulation, as performed
in our assay, may represent the maximum excitability of the CD4+
effector cells; although not antigen-specific, the observed iATP
level may resemble an activation level analogous to that occurring
during an acute infection. Several lines of evidence indicate
cellular hyporesponsiveness and not mere cell number as basis for
our findings: (i) no difference in iATP between patient groups was
observed in unstimulated CD4+-cells. (ii) there was no relationship
between CD4+-iATP and CD4+-cell numbers. (iii) Finally, iATP-
findings were also corroborated by analyses of mitochondrial
transmembrane potential as a biochemically independent measure
that allows a more ‘real time’ monitoring of mitochondrial
function. Our data on higher sensitivity of iATP in comparison to
CD4+-cell counts is well in line with initial reports of natalizumab-
associated PML where no aberrant leukocyte/lymphocyte cell
counts were evident [27–29]. Unaltered iATP in CD8+-cells and
CD8+-cell counts in PML may reflect their physiologic role which
comprises restraining the infection in the CNS in situ, but only
secondarily after the initial immune response that occurs upon
JCV antigen recognition by CD4+-cells and B-cells.
We also observed a strong influence of PLEX on iATP in
natalizumab-associated PML. PLEX rapidly elimininates natali-
zumab and restores lymphocyte migratory function. However, the
PLEX-associated increase of iATP appears to be at least partly
independent from mAb removal, as indicated by the observed
iATP increase in patients undergoing PLEX as a treatment for
non-mAb-associated neuroimmunological diseases. Moreover, as
these non-mAb-associated neuroimmunological diseases include
conditions other than PML, the finding of CD4+-iATP increase
upon PLEX strengthens the hypothesis that this phenomenon is
specific to the PLEX treatment itself rather than due to changing
dynamics of the JCV infection. This effect of PLEX on CD4+-
iATP has not been previously shown, but is consistent with studies
reporting leukocyte proliferation and induction of suppressor cell
function upon PLEX treatment [21–23,30,31]. Both, direct PLEX
effects on lymphocyte activation as well as the specific removal of
natalizumab that restores the ability of immune effector cells to
Table 1. Characteristics/clinical data of subjects analyzed for iATP – Controls.
Age, gender, [gender ratio (f:m)],
course of disease Previous disease and therapy/therapy duration
Healthy Controls (n=59) 36.7611.5 [1.36] NA
MS – no therapy (n =70) 40.8613.2 [1.8] 44 RRMS, 20 SPMS, 6 PPMS NA
MS – natalizumab (n=157) 3769.5 [2.3] 157 RRMS 92 with up to 24 months, 58 with more than 24 months and 7 with 68–78
months of natalizumab-monotherapy
HIV (n =18) 45.7612.2 [0.2] CDC classification: 1 with B2, 2 with B3, 13 with C3. 5 Patients had Kaposi’s
sacroma (HHV8 related), two oral hairy leucoplacia (EBV-related), 4 candida-
esophagitis, 6 oral candidosis, 2 molluscs, 6 Pneumocystis jirovecii
pneumonia, 3 chronic Herpes simplex infections, 1 cryptosporidosis, 1
toxoplasmosis
Individuals assessed for iATP measurement including healthy controls and MS Patients as respective control groups (multiple sclerosis (MS)-patients untreated, or
natalizumab-treated). HIV patients (clinical presentation according to CDC classification) were tested as control patients at risk for opportunistic infections. NA= not
applicable.
doi:10.1371/journal.pone.0018506.t001
iATP in mAb-Related Infections
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Table 2. Clinical data of subjects analyzed for iATP – Natalizumab associated PML.
Age,
gender
Previous disease
and therapy/
therapy duration
Clinical presentation
of PML
Latency between
first symptoms and
diagnosis
Time point of ATP-
measurement during
course of PML
PML diagnosis,
treatment, current
status
PML
Natalizu-
mab 1
52, male MS (diagnosed 1992),
1 year of intermittent
interferon beta-
treatment, 5 years
of azathioprine
(50 mg/d),
176natalizumab
Initially impairment
of cognition in terms
of forgetfulness and
inappropriate
perception and
answers when asked,
mood alterations with
aggressive episodes.
After about 2 months
of drowsiness,
inattention, severe
flaccid left-sided
hemiparesis
PML diagnosed about
two months after initial
symptoms
Initial iATP measurement
about two months after
initial symptoms, before
initiation of therapy, 2.
iATP 5 days hereafter,
3. iATP four weeks after
initial iATP, 4. iATP 4
months after first
measurement, 5. iATP
4.5 months after first
measurement
cMRI, CSF: JC-virus PCR
(repeated). Plasma
exchange and
immunoadsorption,
mirtazapine, mefloquine.
Stable after IRIS, treated
on an outpatient basis
PML
Natalizu-
mab 2
49, male MS (diagnosed 2006),
5 years of intermittent
interferon beta-
treatment, 2 years of
mitoxantrone therapy
(cumulative dose of
85 mg/m2),
296natalizumab
Paresthesia in the
extremities,
impairment of visual
acuity on both eyes
in terms of field
defect due to
retrochiasmatic lesion,
dyslexia
PML diagnosed about
two weeks after initial
symptoms
Initial iATP measurement
about two weeks after
initial symptoms, before
initiation of therapy, 2.
iATP 12 days hereafter,
3. iATP 35 days after
initial iATP
cMRI, CSF: JC-virus PCR
(repeated). Plasma
exchange and
immunoadsorption,
mirtazapine, mefloquine.
Stable after IRIS
PML
Natalizu-
mab 3
37, male MS (diagnosed 1999),
166natalizumab
Myoclonic jerks of
the left arm
PML diagnosed about
two months after initial
symptoms
Initial iATP measurement
about two and a half
weeks after initial
symptoms, after plasma
exchange and
immunoadsorption, 2.
iATP 12 days hereafter
cMRI, CSF: JC-virus PCR
(repeated). Plasma
exchange and
immunoadsorption,
mirtazapine, mefloquine.
Stable after IRIS, treated
on an outpatient basis
PML
Natalizu-
mab 4
57, male MS (diagnosed 2006),
126natalizumab
Initially: cognitive
deficits and
depression. During
the course of PML
drowsiness, right
hemianopsia, aphasia,
flaccid right-sided
hemiparesis
PML diagnosed about
1 week after initial
symptoms, initial ATP-
measurement after
561000
methylprednisolone
and 2 cycles of
immunoadsorption
Initial iATP measurement
about two and a half
weeks after initial
symptoms, before, 2.
iATP 12 days hereafter
cMRI, CSF: JC-virus PCR
(repeated). 561000
methylprednisolone and
4 cycles of
immunoadsorption,
mirtazapine, mefloquine,
stable after IRIS
PML
Natalizu-
mab 5
42, female 3.5 years of intermittent
interferon-treatment,
236natalizumab
Epileptic seizures PML diagnosed about 2
weeks after initial
symptoms
iATP measurement
about 6 weeks after
first symptoms and 3
weeks after 5 cyles of
plasma exchange
cMRI, CSF: JC-virus PCR.
Plasma exchange, 561000
methylprednisolone,
mefloquine, valproate,
levetiracetam, stable after
IRIS, treated on an
outpatient basis
PML
Natalizu-
mab 6
32, male MS (diagnosed 1997),
7 years of interferon
beta-treatment,
346natalizumab
Initially: depression,
right sided hemiataxia
and hemiparesis, gait
ataxia. During the
course of PML
drowsiness and
dysarhria
PML diagnosed about
2 weeks after initial
symptoms
Initial iATP measurement
about 4 weeks after
first symptoms and 1.5
weeks after 6 cyles of
plasma exchange, 2.
iATP measurement 4.5
months hereafter
cMRI, CSF: JC-virus PCR. 6
cycles of plasma
exchange, 561000
methylprednisolone,
3630 g IVIG, mirtazapine,
mefloquine, IRIS
PML
Natalizu-
mab 7
43, female NK NK NK Initial iATP measurement
1 day after 5 cyles of
plasma exchange, 2.
iATP-measurement 1 week
after plasma exchange
NK
PML
Natalizu-
mab 8
35, female MS (diagnosed 1993),
2 years of interferon
beta-treatment,
participation at SENTI-
NEL trial, 5 cycles
mitoxantrone (each
12 mg/m2 body surface),
azathioprine (50 mg/d),
316natalizumab
Impairment of visual
acuity on both eyes,
after immune
reconstitution
syndrome flaccid
paresis of the left arm
PML diagnosed about
1 week after initial
symptoms
iATP measurement 1.5
weeks after initial
symptoms and 2 cycles
of immunoadsorption
cMRI, CSF: JC-virus PCR.
Immunoadsorption,
361000
methylprednisolone,
mirtazapine, mefloquine,
stable after IRIS, treated on
an outpatient basis
MS Patients tested for iATP who developed PML under natalizumab immunotherapy. IRIS = immune reconstitution inflammatory syndrome, NA=not applicable,
NK = not known.
doi:10.1371/journal.pone.0018506.t002
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enter the JC-virus-infected CNS may be clinically relevant. Thus,
PLEX was followed by development of IRIS 4 weeks later, arguing
for effective resurrection of the immune system that can restrain
JCV propagation in infected glial cells [9].
Although not classified as an immunosuppressive drug, a line
of evidence demonstrates that natalizumab may actively inhibit
immune effector cells: mAb-mediated blockade of the a4
integrin has been shown to lead to induction of apoptosis in
murine thymocytes in vitro [32] and of T lymphocytes in an
animal model of autoimmune-mediated neuritis in vivo [33].
This putative inhibition of immune effectors by natalizumab is
unlikely to be mediated through an immediate effect on
cellular bioenergetics, as we did not observe differences in
iATP in our cross-sectional cohort of MS-patients or in our in
vitro analyses. However, we did find a modest decrease in mean
iATP in patients treated for more than 24 months, suggesting a
treatment duration-dependent effect. This was particularly
evident for 7 patients who had received natalizumab for more
than 68 months, including treatment during the pivotal phase
III-SENTINEL trial [18]. In fact, amongst those patients
Table 3. Clinical data of subjects analyzed for iATP – PML and HSVE with various underlying diseases and/or monocloncal
antibodies.
Age,
gender
Previous disease and
therapy/therapy
duration
Clinical presen-
tation of PML/
HSVE
Latency between
first symptoms
and diagnosis
Time point of
ATP-measurement
during course
of PML
PML/HSVE diagnosis,
treatment, current
status
HSVE
Natalizumab
45, female MS (diagnosed 1991),
66natalizumab, 1997–
1998 IFNb-1a i.m., 1998–
1999 mitoxantrone, 1999–
2003 methotrexate
Global aphasia,
impairment of
cognition,
drowsiness
HSVE diagnosed within
two days after initial
symptoms
iATP measurement
within first week of
initial symptoms and
after initiation of
aciclovir treatment
cMRI, CSF: HSV-virus
PCR. 14 days of aciclovir,
stable, treated on an
outpatient basis
PML
spontaneous
70, female None known, no drug
treatment
Dysphasia, memory
disturbance, personality
change, central facial
palsy
PML diagnosed about
two weeks after initial
symptoms
Initial iATP-measure-
ment about two weeks
after first symptoms, 2.
iATP 18 days hereafter
cMRI, CSF: JC-virus PCR.
Mirtazapine, mefloquine,
stable, treated on an
outpatient basis
PML
efalizumab
47, male Psoriasis, fumaric acids,
3 years of methotrexate,
3 years of efalizumab
Progressive flaccid
left-sided hemiparesis
and hemihypesthesia
PML diagnosed about
two weeks after initial
symptoms
iATP measurement 1
month after 5 cycles
of plasma exchange,
shortly before death
cMRI, CSF: JC-virus PCR.
5 cycles of plasma
exchange, 3680 g IVIG,
mirtazapine, mefloquine,
IRIS, death
PML
rituximab 1
60, male Mantle cell lymphoma
(diagnosed November
2008), 3 cycles of R-
CHOP therapy (including
rituximab), 3 cycles of
R-DHAP therapy
Progressive global
aphasia and right-
sided hemiparesis
PML diagnosed about
three weeks after initial
symptoms by
histopathological analysis
of CNS tissue after brain
biopsy
iATP measurement
about 9 months after
initial symptoms
cMRI, CSF: negative JC-
virus PCR, brain biopsy.
Dexamethasone,
cidofovir
PML
rituximab 2
67, male Follicular lymphoma
CD20+ (diagnosed 2000),
adjuvant radiochemo-
therapy, rituximab
Brachiofacial left-
sided hemiparesis
followed by
impairment of
cognition, mood
alterations with
aggressive episodes
three months later
PML diagnosed about
four months after
initial symptoms
iATP measurement
about 9 months after
initial symptoms,
shortly before death
cMRI, CSF: JC-virus PCR.
Mirtazapine, mefloquine,
valganciclovir, duloxetin,
death
PML
HIV 1
38, male HIV (diagnosed 1994),
CDC classification C3, HAART
until February
2009, at time point of
PML diagnosis: HIV RNA in
plasma 544 copies/ml, HIV
RNA in CSF 328 copies/ml
Psychosis, impairment
of cognition, mood
alterations, followed
by right-sided
hemiparesis, aphasia
and epileptic seizures
PML diagnosed about
four weeks after initial
symptoms
iATP measurement
about 8 weeks after
initial symptoms,
before initiation of
antiretroviral therapy
cMRI, CSF: JC-virus PCR.
Mirtazapine, mefloquine,
lopinavir, ritonavir,
epivir, retrovir
PML
HIV 2
38, male HIV (diagnosed December
2009, at the time point of
PML diagnosis), HIV RNA
in plasma 790 copies/ml,
Motor aphasia,
progressive right-
sided hemiparesis,
internuclear
ophtalmoplegia (INO)
to the left side
PML diagnosed about
six weeks after initial
symptoms
iATP measurement
about 4 weeks after
diagnosis
cMRT, CSF: JC-virus PCR,
brain biopsy. Cidofovir,
mirtazapine, initiation of
HAART
PML
psoriasis
immuno-
suppressed
57, female Psoriasis (diagnosed about
30 years ago), pulmonary
sarcoid stage II (diagnosed
2005), oral corticosteroids
(2005–2006), methotrexate
(2006) and fumaric acids
Gait and truncal
(left-sided) ataxia,
fatigue
PML diagnosed few
days after onset of
ataxia
iATP measurement 2
weeks after initial
symptoms
cMRI, CSF: JC-virus PCR,
brain biopsy, cidofovir,
mirtazapine
Clinical characteristics and disease course of patients with or withour preceeding immunodeficient conditions and/or mAb-immunotherapy who developed PML or
Herpes simplex virus encephalitis (HSVE) tested for iATP.
doi:10.1371/journal.pone.0018506.t003
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receiving natalizumab for more than 24 months, there was also
a subset of individuals who actually had iATP levels that were
below the 3rd percentile of HC iATP. These findings could
indicate that a small subgroup of patients may develop impaired
T-cell function upon prolonged natalizumab treatment. Given
the increased risk of PML development (1 in 600) with increased
natalizumab treatment duration, that has been recently reported
by the FDA [34], it is intriguing to speculate this increased risk
may, at least in part, be related to an impairment of T-cell
function arising with natalizumab administration over time.
However, a larger patient cohort needs to be investigated
longitudinally to corroborate our initial findings and to further
assess the correlation between the increased risk of PML (that is
associated with treatment duration) and the apparent decrease
in iATP.
In conclusion, although the pathomechanisms of PML remain
elusive, our data indicate that bioenergetic parameters relating
to CD4+-mediated immunity may assist in neuroimmunological
disease risk stratification and monitoring under mAb-immuno-
therapy, and may be a more sensitive measure than the CD4+
cell count, that is the only suggested measure of immunocom-
petence under natalizumab therapy to date [40]. Our data also
indicate that iATP is a measure of immune cell responsiveness
that is independent of total cell numbers, as consistently shown
in our study and in the initial study performed to obtain FDA
approval for the use of iATP measurements in the context of
transplantation [41]. In order to determine the validity of
CD4+-iATP in predicting PML a prospective study in which
iATP levels are ascertained from pre-PML samples is required.
However, given the current incidence of natalizumab-associated
PML such a study would necessitate the involvement of
thousands of individuals. It is conceivable, that bioenergetic
measurements, particularly in conjunction with other parame-
ters such as JC-viruria/viraemia, CD34+-cell numbers and
molecular JCV-monitoring [4], could contribute to disease
prediction. The assessment of anti-JCV antibodies with
presumably high negative predictive value [26] with the
longitudinal determination of iATP levels that potentially
harbours a high positive predictive value, could constitute a
clinically useful combination of assays.
Methods
Patients and sample collection
The study was approved by the ethics committee of the
Ruhr-University Bochum and investigations were performed
after written informed consent. All patients were devoid of acute
infections (clinically, white blood cell count, C-reactive protein).
Clinical characteristics of mAb-associated PML-cases (n = 11),
two cases of HIV-associated PML, and one case each of PML
without previous immunotherapy, a patient with psoriasis who
developed PML under immunosuppressive therapies and
fumaric acids and natalizumab-associated herpes-simplex en-
cephalitis (HSV-E) are summarized in the tables 1–3. Two MS-
patients who developed PML following natalizumab monother-
apy (PML 1 and 3 nataliz, fig. 1) were recently reported [9,10].
Clinical characteristics of respective control groups are given in
table 1 (59 healthy individuals (HC), 70 therapy-naı¨ve MS-
patients). Of 157 natalizumab-treated MS-patients investigated,
seven had on average 75 months (range 68–78 months) of
natalizumab exposure since participation in the pivotal
SENTINEL- phase III clinical trial [24]. 12 de novo natalizu-
mab-treated MS-patients were followed longitudinally for up to
1 year. 5 patients undergoing PLEX as escalating therapy for
severe relapse (4 glucocorticosteroid-refractory MS-relapses and
one monoclonal gammopathy; 3–5 PLEX-cycles, 30 ml per kg
body weight, 5% human albumin) were analyzed longitudinally.
Eighteen HIV-patients were at risk for opportunistic infections
despite highly active antiretroviral therapy (HAART) on clinical
grounds due to previous infections, e.g. candidiasis, pneumonia
and herpes simplex viral infections (according to the classifica-
tion of Centers for Disease Control and Prevention (CDC)
one patient with B2, 2 with B3 and 13 with C3, see table 1 for
details).
Assessment of ATP production in CD4+ and CD8+ cells
After stimulation of sodium-heparin collected whole blood
samples (phytohaemagglutinin, PHA, 2.5 mg/ml, 15 h; Sigma-
Aldrich, Taufkirchen, Germany) CD4+-cells were immunose-
lected using magnetic beads (Invitrogen, Karlsruhe, Germany).
Following cell lysis, ATP-concentrations were measured in a
FDA-approved luciferase-activity based assay according to the
manufacturer’s specifications in quadruplicates (Immuno-
KnowTM, Cylex, Columbia, USA). Between day coefficient of
variation (CV) was 9.3% in HC including natural biological
variation over several months. ATP-concentration in CD8+-cells
was assessed following the same protocol in an off-label
experimental assay. For in vitro experiments, whole blood
samples of healthy controls and MS-patients (n = 9) were
incubated for 24 hours with natalizumab (BiogenIdec, Cam-
bridge, USA) with a concentration of 5 mg/ml, equivalent to
serum levels under the therapeutic dose of 300 mg natalizumab-
infusion in MS-patients. As isotype control antibody (isoAb)
IgG4 (Sigma, Deisenhofen, Germany) was used.
Absolute cell numbers (CD4+/CD8+/CD19+/CD56+) were
determined by flow cytometry (FACS-Calibur, Becton Dick-
inson, Heidelberg, Germany). TrucountTM tubes containing
TrucountTM control beads (Becton Dickinson) were used as
internal standard for absolute cell count determination in the
lymphocyte gate. Due to logistical reasons cell counts could not
be obtained in the patient with natalizumab-associated HSV-
encephalitis.
Flow cytometric analysis of mitochondrial
transmembrane potential (DYm) in CD4
+ cells
Changes of mitochondrial transmembrane potential (DYm) in
PMA-treated (2.5 mg/ml, 30 min; Sigma-Aldrich) CD4+-cells
(anti-CD4-APC, Becton Dickinson) of HC and HIV (n = 12) were
measured by flow cytometry of mitochondrial tetramethyl
rhodamine methylester load (TMRM - 2 mM, 10 min; Invitrogen)
[25]. Mean fluorescence intensity (MFI) of TMRM in CD4+-
labelled cells was assessed with a minimum of 10.000 CD4+-cells
analyzed (Canto II, Becton Dickinson).
Statistical analysis
Two-sided parametric t-test was performed for all statistical
analyses except Pearson correlation test for iATP/CD4+-cell
numbers (GraphPad Prism, La Jolla, USA) and Kendall’s Tau for
iATP/DYm-correlation (SPSS). p,0.05 (*), p,.001 (**) and
p,.0001 (***) were considered significant. Data is given as mean
6 standard error (SEM).
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